NCT07882030Not yet recruiting
Early Administration of Angong Niuhuang Pill for Disabling Acute Ischemic Stroke (EAGER Trial)
Efficacy and Safety of Early Administration of Angong Niuhuang Pill in Patients With Disabling Acute Ischemic Stroke: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of early administration of Angong Niuhuang Pill in patients with disabling acute ischemic stroke. Approximately 1,200 eligible participants will be randomly assigned in a 1:1 ratio to receive Angong Niuhuang Pill or a matching placebo for 5 consecutive days. Eligible participants will be adults aged 18 to 80 years with imaging-confirmed acute ischemic stroke involving the anterior circulation, a baseline National Institutes of Health Stroke Scale (NIHSS) score of 10 to 19, symptom onset or last known well within 24 hours before randomization, and a pre-stroke modified Rankin Scale (mRS) score of 0 or 1. The primary efficacy outcome is the proportion of participants achieving functional independence at 90 days after randomization, defined as an mRS score of 0 to 2. Secondary outcomes include excellent functional outcome, the distribution of mRS scores at 90 days, change in the Barthel Index, changes in NIHSS scores, neurological improvement, and symptomatic intracranial hemorrhage. Safety outcomes include serious adverse events, all-cause mortality, and changes in hepatic and renal laboratory parameters.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1200 (estimated)
- First submitted
- 27 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Stroke
- NCT number
- NCT07882030
What you commit to
- Study type: Interventional
- Planned participants: 1200
- From Oct 2026 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe drug or alcohol abuse.
- Participation in another clinical trial within 3 months before screening.
- Use of Angong Niuhuang Pill within 1 month before screening.
Other illness
- Presence of symptoms or clinical conditions considered unsuitable for administration of Angong Niuhuang Pill, including axillary body temperature below 36°C, systolic blood pressure below 120 mmHg, or loose stool within 24 hours before stroke onset, characterized by loose consistency and increased water content.
- Brain imaging findings indicating encephalitis, brain tumor, brain abscess, or another condition that may mimic acute ischemic stroke, or evidence of epidural hematoma, intracranial hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, or other intracranial bleeding.
- Known allergy to Angong Niuhuang Pill or any contraindication to its administration.
- History of arterial aneurysm, including intracranial or peripheral arterial aneurysm.
- History of psychotic disorder or dementia.
- Severe organ dysfunction or other serious systemic disease; any active malignancy or ongoing anticancer treatment; or life expectancy of less than 3 months.
- Clinically significant hypersensitivity or a history of allergy to two or more drugs or foods.
- Inability to understand and/or comply with study procedures or follow-up requirements because of psychiatric, cognitive, or other disorders.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.
Lab values
- Thrombocytopenia, defined as a platelet count below 100 × 10\^9/L; hematologic disease or other systemic bleeding tendency; or lower-extremity deep vein thrombosis.
- Severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 1.5 times the upper limit of normal, or serum creatinine more than 1.5 times the upper limit of normal.
Other
- Patients who have undergone or are planned to undergo decompressive craniectomy.
- Pregnancy or breastfeeding at screening.
Who the study is looking for
- Age 18 to 80 years, inclusive.
- Acute ischemic stroke involving the anterior circulation, confirmed by brain computed tomography (CT) or magnetic resonance imaging (MRI).
- Baseline National Institutes of Health Stroke Scale (NIHSS) score of 10 to 19, inclusive.
- Symptom onset or last known well within 24 hours before randomization.
- Pre-stroke modified Rankin Scale (mRS) score of 0 or 1.
- The participant or legally authorized representative understands the study procedures and voluntarily provides written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.